Moderna's Melanoma Therapy Yields Promising Results in Late-Stage Trial

Moderna and Merck's collaborative work on an mRNA cancer therapy has yielded positive results in a late-stage trial. The treatment, which is used in combination with Keytruda, has shown statistically significant improvement over using Keytruda alone. This news has sent Moderna's shares soaring by nearly 90%, while Merck saw its stock gain 10%.

The therapy, known as Intismeran, targets melanoma and has the potential to change the way cancer is treated broadly. Dr. Ryan Sullivan, Director of Cutaneous Medical Oncology at Mass General Brigham Cancer Institute, called it a 'big deal' for the field.

Analysts are cautiously optimistic about the results, with some warning that the full data has yet to be released and manufacturing personalized vaccines at scale could be complex and expensive. However, many see this as a significant breakthrough with potential for multi-billion dollar sales in the future.